Möchten Sie immer auf dem neuesten Stand bleiben?
Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.
-
Exclusive agreement gives MMA.INC direct participation in sales of U.S. manufactured, third party tested peptide recovery products across its global combat sports ecosystem Highlights MMA.INC enters...
-
On track for planned IND submission in mid-2026 and Phase 1 initiation in the second half of 2026 for XTX501, a potential best-in-class bispecific PD-1 / masked IL-2 Presented new preclinical data...
-
TORONTO, May 12, 2026 (GLOBE NEWSWIRE) -- George Weston Limited (TSX: WN) (“GWL” or the “Company”) today announced its consolidated unaudited results for the 12 weeks ended March 28, 2026(2). ...
-
Company closed PIPE financing with gross proceeds of up to $175 million, including the possible exercise of warrants, from long-term global investors. Proceeds are expected to fund the Company through...
-
Hyderabad, India, May 12, 2026 (GLOBE NEWSWIRE) -- According to Mordor Intelligence, the global oil refining market is projected to grow from USD 64.44 billion in 2026 to reach USD 75.08 billion by...
-
Global humanitarian charity Human Appeal has launched the “Hajj 10K Steps Challenge,” running from May 17–26, 2026, to coincide with the Hajj pilgrimage.
-
Announced strategic collaboration with Mayo Clinic, focused on improving care in type 1 diabetes and accelerating development of SC451 Continued progress toward starting SC451 Phase 1 trial later...
-
Net Revenue increased 4.5% to $312.0 millionGAAP Net Income increased 188.6% to $1.4 millionAdjusted Net Income decreased 3.6% to $3.4 millionAdjusted EBITDA increased 3.8% to $ $10.1 million LAS...
-
Topline global pivotal Phase 3 data for firmonertinib in first-line EGFR exon 20 insertion mutant NSCLC expected mid-2026IND clearance of ARR-002, ArriVent’s dual-targeting MUC16/NaPi2b tetravalent...
-
aTyr Pharma Provides Regulatory and Clinical Update for Efzofitimod in Pulmonary Sarcoidosis Following FDA Type C Meeting